Amorfix seeking partner for Alzheimer’s test

Amorfix Life Sciences (TSX:AMF) has updated its Alzheimer’s disease diagnostic program, saying that it has achieved 85% specificity and sensitivity with its EP-AD CSF diagnostic test and is now actively seeking a development partner to bring this new asset to the market as quickly as possible. Unlike tests that measure changes in the levels of [...]

Amorfix suspends blood testing for vCJD

Amorfix Life Sciences (TSX:AMF) has suspended development to commercialize its blood test for variant Creutzfeldt-Jakob disease (vCJD) after two new recently developed versions of the test did not yield positive results. “Although we were able to achieve unprecedented sensitivity with brain prions diluted into blood, we have been unable to detect blood prions with the [...]